TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study
The triple combination of TACE, regorafenib, and PD-1 inhibitors demonstrated superior clinical efficacy compared with TACE-regorafenib dual therapy in advanced HCC patients after targeted therapy failure, with optimal outcomes observed following earlier regorafenib initiation and an acceptable safety profile.
Authors
- Weijun Fan
- Quan-Jun Yao
- Guangshao Cao
- Gang Wu (ORCID: https://orcid.org/0009-0002-5503-1384)
- Hong-Tao Hu (ORCID: https://orcid.org/0000-0002-5432-4014)
- Li Yan (ORCID: https://orcid.org/0000-0002-2159-0009)
- Hang Yuan (ORCID: https://orcid.org/0000-0003-3761-2708)
- Fei Xu (ORCID: https://orcid.org/0009-0000-2452-937X)
- Xiang Geng (ORCID: https://orcid.org/0009-0008-2311-9705)
- Ho-Young Song
Institutions
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Henan Provincial People's Hospital (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fonc.2025.1652319
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00